Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: curcumin formulations - Signpath Pharma

Drug Profile

Research programme: curcumin formulations - Signpath Pharma

Alternative Names: Diferuloylmethane formulations - Signpath Pharma; Extended-release PLGA-curcumin; Nano curcumin; Nanocurc; PLGA-liposomal-curcumin; Polylactic coglycolic acid liposomal curcumin; Polymeric nanocurcumin

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins Medical Institutions; University of North Texas Health Science Center
  • Developer Signpath Pharma
  • Class Catechols
  • Mechanism of Action Inflammation mediator modulators; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Diabetic complications; Neurodegenerative disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-complications(Prevention) in USA (SC)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top